JPWO2016027781A1 - Salts and crystals of monocyclic pyridine derivatives - Google Patents

Abstract

Provided is a salt or crystal thereof comprising an organic carboxylic acid selected from the group consisting of succinic acid and maleic acid, and a compound represented by formula (I), which can be used as an active pharmaceutical ingredient. [Chemical 1]

Description

  The present invention relates to a salt of a monocyclic pyridine derivative having an FGFR inhibitory action and a crystal thereof.

FGF (fibroblast growth factor) is known as a growth factor that controls various physiological functions such as cell proliferation, cell migration, cell invasion, cell survival, differentiation induction, wound healing, and angiogenesis. .
FGF regulates various physiological functions through FGF receptors (FGFR: FGFR1, FGFR2, FGFR3, FGFR4) which are receptor tyrosine kinases. FGFR is composed of three types: an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. FGF binds to the FGFR extracellular domain to form a receptor dimer. Then, after intracellular tyrosine kinases are activated, intracellular signals mainly via MAPK (mitogen-activated protein kinase) / ERK (extracellular signal-regulated kinase) pathway or PI3K (phosphatidylinositol 3-kinase) / Akt pathway. Is transmitted.

  On the other hand, as a result of FGF / FGFR signal abnormality induced by FGF production enhancement, FGFR gene amplification, FGFR overexpression, FGFR fusion protein formation, FGFR mutation, etc., breast cancer, bladder cancer, EMS (8p11 myoproliferative syndrom), gastric cancer, It has been reported that various cancers such as endometrial cancer and prostate cancer are caused (Non-patent Document 1). Furthermore, non-small cell lung cancer, small cell lung cancer, ovarian cancer, sarcoma, colon cancer, melanoma, glioblastoma, astrocytoma, or head and neck cancer as a cancer with FGF / FGFR signal abnormality (Non-patent Document 2) 3), thyroid cancer (Non-patent document 4), pancreatic cancer (Non-patent documents 5 and 6), liver cancer (Non-patent document 7), skin cancer (Non-patent document 8), renal cancer (Non-patent document 9) And squamous cell carcinoma of the lung (Non-Patent Documents 10, 11, and 12) have been reported.

In endothelial cells, FGF / FGFR signal is a major angiogenesis signal along with VEGF (vascular endothelial growth factor) / KDR (kinase-insert domain-containing receptor) signal, and also cancer stromal cells (fibroblasts). (Cell non-patent document 1).
Therefore, an FGFR inhibitor targeting FGF / FGFR signal is expected as an antitumor agent based on a suppressive action on the abnormal signal or angiogenic signal in cancer with abnormal FGF / FGFR signal. Recently, selective FGFR inhibitors that are considered to be less susceptible to other signal confronting effects, such as FGFR1, FGFR2 and FGFR3, which are clearly different in structure from the compounds of the present invention. Selective FGFR inhibitors have been reported. However, in the development of human anti-tumor agents, selective FGFR inhibitors lag behind anti-tumor agents that simultaneously target both FGF / FGFR signals and VEGF / KDR signals, and are still commercially available. None (Non-Patent Documents 13 and 14, Patent Documents 1 and 2). Patent Document 3 discloses a pyrimidine derivative, but does not disclose an inhibitory action on signal abnormality of FGF / FGFR signal. Patent Document 4 discloses a pyridine derivative or a pyrimidine derivative that suppresses angiogenesis induced by VEGF and FGF. However, these documents do not disclose the compounds according to the present invention.

International Publication No. 2008/075068 International Publication No. 2006/000420 International Publication No. 2002/032872 International Publication No. 2004/020434

Nicholas et al., “Fibroblast growth factor signaling: from development to cancer”, Nature Reviews Cancer. 2010; 10: 116-129 Joergen WESCHE et al., Fibroblast growth factors and their receptors in cancer, Biochem J. 2011: 437; 199-213 Gennaro Daniele et al., FGF Receptor Inhibitors: Role in Cancer Therapy, Curr Oncol Rep. 2012; 14: 111-119 Rosanne St. Bernard et al., Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma, Endocrinology. 2005; 146: 1145-1153 Toshiyuki Ishiwata et al., Enhanced Expression of Fibroblast Growth Factor Receptor 2 IIIc Promotes Human Pancreatic Cancer Cell Proliferation, Am J Pathol. 2012; 180: 1928-1941 G Chen et al., Inhibition of inherent SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression, Br J Cancer. 2010; 102: 188-195 Dorothy M. French et al., Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models, PLoS One. 2012; 7: e36713 Armelle Logie et al., Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans, Hum Mol Genet 2005; 14: 1153-1160 Tsimafeyeu I et al., Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma, Scand J Urol Nephrol 2011; 45: 190-195 Jonathan Weiss et al., Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer, Sci Transl Med. 2010; 2: issue62 62-93 Hidefumi Sasaki et al., Increased FGFR1 copy number in lung squamous cell carcinomas, Mol Med Report. 2012; 5: 725-728 The Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers, Nature 2012; 489: 519-525 Paul R Gavine et al., AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family, Cancer Res. 2012; 72: 2045-2056 Vito Guagnano et al., Discovery of 3- (2,6-Dichloro-3,5-dimethoxy-phenyl) -1- {6- [4- (4-ethyl-piperazin-1-yl) -phenylamino] -pyrimidin -4-yl} -1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase, J Med Chem. 2011; 54: 7066-7083

A compound represented by the following formula (I) (5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy ) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide, hereinafter referred to as Compound (I)) has FGFR1, FGFR2 and FGFR3 inhibitory activity.
In general, the properties of compounds used as pharmaceuticals and salts thereof and crystals thereof have a great influence on the bioavailability of drugs, the purity of drug substances, the formulation of pharmaceuticals, and the like. Accordingly, an object of the present invention is to provide a salt of Compound (I) and a crystal thereof having applicability as an active pharmaceutical ingredient.

  As a result of intensive studies on the compound (I) in view of the above circumstances, the present inventors have found a salt of the compound (I) and crystals thereof and completed the present invention.

That is, the present invention provides the following [1] to [17].
[1] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} represented by the following formula (I) A salt comprising oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid or maleic acid,
[2] The salt according to [1], which is a salt composed of succinic acid,
[3] The salt according to [1], which is a salt consisting of maleic acid,
[4] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxy Ethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 succinate, salt according to [2],
[5] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxy Ethoxy) -N-methyl-1H-indole-1-carboxamide 0.5 succinate, salt according to [2],
[6] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxy The salt according to [1], which is ethoxy) -N-methyl-1H-indole-1-carboxamide maleate,
[7] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} represented by the following formula (I) Crystals of a salt consisting of (oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid or maleic acid,
[8] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} represented by the following formula (I) Crystals of a salt consisting of oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid,
[9] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} represented by the following formula (I) Oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and a crystal of a salt consisting of maleic acid,
[10] 5-({2-[({4- [1- (2-hydroxyethyl) piperidine] having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 22.4 ° in powder X-ray diffraction. -4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 succinate crystals,
[11] In the powder X-ray diffraction, the crystals of [10] having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 22.4 °, 25.3 °, and 23.3 °,
[12] 5-({2-[({4- [1- (2-hydroxyethyl) piperidine] having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 19.8 ° in powder X-ray diffraction -4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 0.5 succinate crystals (α ),
[13] 5-({2-[({4- [1- (2-hydroxyethyl) piperidine] having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 20.1 ° in powder X-ray diffraction -4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide maleate crystals,
[14] In a ¹³ C solid state NMR spectrum, 5-({2-[({4- [1- (2) having peaks at chemical shifts (± 0.5 ppm) of 108.5 ppm, 155.1 ppm and 179.9 ppm. -Hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 Succinic acid Salt crystals,
[15] Crystal of [14] having peaks at chemical shift (± 0.5 ppm) 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm in ¹³ C solid state NMR spectrum,
[16] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridine-4- having the powder X-ray diffraction pattern of FIG. Yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 succinate crystals,
[17] A pharmaceutical composition comprising the salt or crystal according to any one of [1] to [16] as an active ingredient.

  The salt of compound (I) and the crystal thereof provided by the present invention have properties as shown in Examples, and also have hygroscopic characteristics as shown in the data of Test Examples described later. It can be used as a drug substance for pharmaceuticals.

1 is a powder X-ray diffraction pattern of the crystal of compound (I) · 1.5 succinate obtained in Example 1. FIG. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 2 is a powder X-ray diffraction pattern of the crystal (α) of compound (I) · 0.5 succinate obtained in Example 2. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 3 is a powder X-ray diffraction pattern of the crystal of compound (I) · maleate obtained in Example 3. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. 4 is a 13C solid state NMR spectrum of the crystal of compound (I) · 1.5 succinate obtained in Example 1. FIG. FIG. 5 is a graph showing the hygroscopicity of the crystals of compound (I) · 1.5 succinate obtained in Example 1. The horizontal axis represents relative humidity, and the vertical axis represents weight change. FIG. 6 is a powder X-ray diffraction pattern of the compound (I) · free form crystal (Free Form A) obtained in Production Example 1-15. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 7 is a powder X-ray diffraction pattern of the compound (I) · free form crystal (Free Form B) obtained in Reference Example 1. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 8 is a powder X-ray diffraction pattern of the compound (I) · free form crystal obtained in Reference Example 2 (Free Form Hydrate). The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 9 is a powder X-ray diffraction pattern of the compound (I) mesylate crystal obtained in Reference Example 3. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 10 is a powder X-ray diffraction pattern of the compound (I) -tosylate crystal obtained in Reference Example 4. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 11 is a powder X-ray diffraction pattern of crystals of compound (I) .benzoate obtained in Reference Example 5. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 12 is a powder X-ray diffraction pattern of the crystal of compound (I) • fumarate obtained in Reference Example 6. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 13 is a powder X-ray diffraction pattern of the crystal (α) of compound (I) · 0.5 succinate obtained in Example 4. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. 14 is a powder X-ray diffraction pattern of compound (I) · 0.5 succinate crystal (β) obtained in Example 5. FIG. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity. FIG. 15 is an amorphous powder X-ray diffraction pattern of the compound (I) · 1.5 succinate obtained in Example 6. The horizontal axis indicates the diffraction angle (2θ), and the vertical axis indicates the peak intensity.

  Next, the salt of the compound (I) of the present invention, the crystal thereof, and the production method thereof will be described in detail.

  In the present specification, the “salt” means a chemical substance composed of the basic component compound (I) and a specific equivalent number of acids relative to the compound (I).

  Examples of the “salt” used in the present specification include a salt with an inorganic acid, a salt with an organic acid, a salt with an acidic amino acid, and the like. Among them, a pharmaceutically acceptable salt is preferable.

  Examples of salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of salts with organic acids include, for example, acetic acid, succinic acid, fumaric acid. Salts with organic carboxylic acids such as acid, maleic acid, tartaric acid, malic acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid (mesyl acid), ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid Examples thereof include salts with organic sulfonic acids such as (tosylic acid), among which succinic acid and maleic acid are preferable, and succinic acid is particularly preferable.

  Examples of salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like.

  The salt of the present invention may be an anhydride, hydrate or solvate. In this specification, the hydrate or solvate refers to a solid formed by combining Compound (I) or a salt thereof with a water molecule or a solvent molecule, respectively, and the solid may be a crystal. Well, as a solvent of the solvate, for example, ketone solvents such as acetone, 2-butanone and cyclohexanone; ester solvents such as methyl acetate and ethyl acetate; 1,2-dimethoxyethane and t-butyl methyl ether And ether solvents; alcohol solvents such as methanol, ethanol, 1-propanol and isopropanol; polar solvents such as N-methyl-2-pyrrolidone, N, N-dimethylformamide and dimethyl sulfoxide. The number of water molecules or solvent molecules for compound (I) or a salt thereof is not particularly limited, and may be one molecule or two molecules, for example.

  In the present specification, “crystal” refers to a crystal of compound (I) or a salt thereof. Thus, for example, a crystal of compound (I) · 1.5 succinate is a crystal of a salt formed from compound (I) and succinic acid, and succinic acid is added to one molecule of compound (I). It means a salt crystal containing 1.5 molecules.

In this specification, as a preferable crystal, in powder X-ray diffraction,
Compound (I) 1.5 succinate crystals having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 22.4 °;
Crystals of compound (I) · 1.5 succinate having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 22.4 ° and 25.3 °;
Crystals of compound (I) 1.5 succinate having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 22.4 °, 25.3 ° and 23.3 °;
Compound (I) 1.5 succinic acid having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 22.4 °, 25.3 °, 23.3 °, 13.2 ° and 22.0 ° Salt crystals;
Diffraction angle (2θ ± 0.2 °) 22.4 °, 25.3 °, 23.3 °, 13.2 °, 22.0 °, 19.3 °, 15.7 °, 22.7 °, Crystals of compound (I) · 1.5 succinate having diffraction peaks at 20.6 ° and 16.0 °;
Crystal (α) of compound (I) 0.5 succinate having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 19.8 °;
Crystals of compound (I) 0.5 succinate (α) having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 19.8 ° and 15.7 °;
Crystals of compound (I) 0.5 succinate (α) having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 19.8 °, 15.7 ° and 13.9 °;
Compound (I) 0.5 succinic acid having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 19.8 °, 15.7 °, 13.9 °, 21.4 ° and 25.0 ° Salt crystals (α);
Diffraction angle (2θ ± 0.2 °) 19.8 °, 15.7 °, 13.9 °, 21.4 °, 25.0 °, 20.6 °, 18.2 °, 26.8 °, Compound (I) 0.5 succinate crystals (α) having diffraction peaks at 18.8 ° and 22.4 °;
Compound (I) -0.5 succinate crystal (β) having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 16.6 °;
Compound (I) -0.5 succinate crystal (β) having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 16.6 ° and 19.7 °;
Crystals of compound (I) and 0.5 succinate (β) having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 16.6 °, 19.7 ° and 15.7 °;
Compound (I) 0.5 succinic acid having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 16.6 °, 19.7 °, 15.7 °, 9.3 ° and 14.3 ° Salt crystals (β);
Diffraction angle (2θ ± 0.2 °) 16.6 °, 19.7 °, 15.7 °, 9.3 °, 14.3 °, 21.8 °, 20.6 °, 18.7 °, Crystals (β) of compound (I) 0.5 succinate having diffraction peaks at 18.1 ° and 26.5 °;
Compound (I) maleate crystal having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 20.1 °;
Compound (I) maleate crystals having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 20.1 ° and 17.0 °;
Crystals of Compound (I) maleate having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 20.1 °, 17.0 ° and 16.2 °;
Crystals of compound (I) maleate having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 20.1 °, 17.0 °, 16.2 °, 22.8 ° and 21.9 ° ;
Diffraction angle (2θ ± 0.2 °) 20.1 °, 17.0 °, 16.2 °, 22.8 °, 21.9 °, 25.8 °, 9.0 °, 15.2 °, Compound (I) maleate crystals having diffraction peaks at 24.3 ° and 19.6 °;
Compound (I) -1.5 succinate crystals having peaks at chemical shifts (± 0.5 ppm) 108.5 ppm, 155.1 ppm and 179.9 ppm in the ¹³ C solid state NMR spectrum;
Or
Compound (I) 1.5 succinate having peaks at chemical shift (± 0.5 ppm) 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm in ¹³ C solid state NMR spectrum And the like.

  The diffraction peaks in the powder X-ray diffraction described above are: compound (I) · 1.5 succinate crystal, compound (I) · 0.5 succinate crystal (α) and (β), compound (I) )-It is unique to each maleate crystal and is a diffraction peak characteristic of the crystal.

  In general, since the diffraction angle (2θ) in powder X-ray diffraction may cause an error within a range of ± 0.2 °, the above diffraction angle value includes a numerical value within a range of about ± 0.2 °. Need to be understood. Therefore, in a specific salt, not only a crystal in which the diffraction angle of a peak in powder X-ray diffraction completely matches, but also a crystal in which the diffraction angle of a peak matches with an error of about ± 0.2 ° is the same. include.

  In this specification, for example, “having a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 22.4 °” means “having a diffraction peak at a diffraction angle (2θ) of 22.2 ° to 22.6 °. The same applies to other diffraction angles.

  In general, the peak intensity or half-value width of the diffraction angle (2θ) in powder X-ray diffraction is the difference in measurement conditions and the size and shape of each particle of a powder crystal used as a measurement sample even if the crystal form is the same. Due to variations, it varies from measurement to measurement, and a constant peak intensity or full width at half maximum is not always indicated. Therefore, in the comparison of powder X-ray diffraction patterns, even if there is a difference in peak intensity or half-value width at the same diffraction angle (2θ), the difference does not mean that the difference is derived from different crystal forms. Therefore, the crystal of the salt of the powder X-ray diffraction pattern having such a difference with respect to the diffraction peak characteristic of the crystal of the specific salt of the present invention has the same crystal form as the crystal of the salt of the present invention. It means that there is. Further, in the present specification, “having the powder X-ray diffraction pattern of FIG. 1” means not only the case where the powder X-ray diffraction pattern having a characteristic diffraction peak completely matches the pattern shown in FIG. This means that the powder X-ray diffraction pattern shown in FIG. 1 is obtained even in the case of a powder X-ray diffraction pattern having the same diffraction angle but different peak intensity or half width. Therefore, it means that all crystals having such a powder X-ray diffraction pattern are the same crystals as the crystal of the present invention.

In this specification, “chemical shift (± 0.5 ppm) 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm” means “normal measurement conditions or substantially the same as the present specification. ¹³ C solid state NMR spectra were measured under the same conditions, and peaks substantially equivalent to chemical shifts (± 0.5 ppm) of 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm, respectively. It means "having".

In determining whether or not it has “substantially equivalent peaks”, in general, the chemical shift (ppm) in a ¹³ C solid state NMR spectrum can cause an error within a range of ± 0.5 ppm. The value of should be understood as including values in the range of about ± 0.5 ppm. Therefore, the present invention includes not only crystals in which the chemical shift in the ¹³ C solid state NMR spectrum is completely matched but also crystals in which the chemical shift is matched with an error of about ± 0.5 ppm. Therefore, in the present specification, for example, “having a peak at 27.1 ppm of chemical shift (± 0.5 ppm)” means “having a peak at 26.6 ppm to 27.6 ppm of chemical shift” The same applies to chemical shifts in other ¹³ C solid state NMR spectra.

  Below, the manufacturing method of the salt of the compound (I) and crystal | crystallization which are one Embodiment of this invention is demonstrated.

Production of Compound (I) Compound (I) can be synthesized by the method described in Production Example 1 described later.

Method for Producing Compound (I) Salt The salt of compound (I) according to the present invention can be obtained by a method for producing an ordinary salt. Specifically, for example, compound (I) is heated or suspended in a solvent as necessary to suspend or dissolve it, and then an acid is added to the resulting suspension or solution and cooled at room temperature or cooled. However, it can be produced by stirring or standing for several minutes to several days. By these production methods, the salt of the compound (I) can be obtained as a crystal or amorphous. Amorphous can also be obtained by subjecting these production methods to operations such as freeze-drying as necessary. Examples of the solvent used here include alcohol solvents such as ethanol, 1-propanol and isopropanol; acetonitrile; ketone solvents such as acetone and 2-butanone; ester solvents such as ethyl acetate; saturated carbonization such as hexane and heptane. Examples of the hydrogen solvent include ether solvents such as t-butyl methyl ether or water. These solvents may be used alone or in combination of two or more.

Method for Producing Crystal of Compound (I) or a Salt thereof Crystal of Compound (I) or a salt thereof can be produced by the above-described method for producing Compound (I) or a method for producing a salt thereof, or Compound (I) It can also be produced by dissolving I) or a salt thereof in a solvent by heating, cooling with stirring and crystallization.

  Compound (I) or a salt thereof used for crystallization may be in any form, and may be a solvate, hydrate, or anhydride, and may be amorphous or crystalline (from a plurality of crystal polymorphs). Or a mixture thereof.

  Solvents used for crystallization are, for example, alcohol solvents such as methanol, ethanol, isopropanol and 1-propanol; acetonitrile; amide solvents such as N, N-dimethylformamide; ester solvents such as ethyl acetate; hexane and heptane Saturated hydrocarbon solvents such as acetone; ketone solvents such as acetone and 2-butanone; ether solvents such as t-butyl methyl ether or water. These solvents may be used alone or in combination of two or more.

  The amount of the solvent used can be appropriately selected with the lower limit being the amount in which the compound (I) or a salt thereof is dissolved by heating or the amount allowing the suspension to be stirred, and the upper limit being the amount that does not significantly reduce the yield of crystals. .

  In crystallization, seed crystals (such as crystals of desired compound (I) or a salt thereof) may or may not be added. Although the temperature which adds a seed crystal is not specifically limited, Preferably it is 0-80 degreeC.

  The temperature at which compound (I) or a salt thereof is dissolved by heating may be appropriately selected according to the solvent, and the temperature at which compound (I) or a salt thereof is dissolved is preferably selected. It is the range of the temperature which starts reflux, More preferably, it is 55-80 degreeC.

  Cooling during crystallization can give crystals containing different forms of crystals (polymorphs) when rapidly cooled, so it is desirable to adjust the cooling rate appropriately in consideration of the effects on crystal quality and particle size. Preferably, cooling is performed at a rate of 5 to 40 ° C./hour, for example. More preferably, it is cooling at a rate of, for example, 5 to 25 ° C./hour.

  The final crystallization temperature can be appropriately selected from the yield and quality of crystals, but is preferably −25 to 30 ° C.

  The crystallized crystal is separated by a normal filtration operation, and the crystal separated by filtration as necessary is washed with a solvent and further dried to obtain the desired crystal. As the solvent used for washing the crystals, the same crystallization solvent can be used. Preferable examples include ethanol, acetone, 2-butanone, ethyl acetate, diethyl ether, t-butyl methyl ether, and hexane. These solvents may be used alone or in combination of two or more.

  The crystals separated by the filtration operation can be appropriately dried by being left in the air or a nitrogen stream or by heating.

  The drying time may be appropriately selected according to the production amount, drying apparatus, drying temperature, etc. until the residual solvent falls below a predetermined amount. Moreover, drying can be performed under ventilation or under reduced pressure. The degree of vacuum may be appropriately selected according to the production amount, the drying device, the drying temperature, and the like. The obtained crystals can be left in the air after drying, if necessary.

  The salt of Compound (I) and crystals thereof can be formulated by a conventional method. Examples of the dosage form include oral preparations (tablets, granules, powders, capsules, syrups, etc.), injections ( For intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, etc.), external preparations (transdermal absorption preparations (ointments, patches, etc.), eye drops, nasal drops, suppositories, etc.) be able to.

When producing an oral solid preparation, an excipient, a binder, a disintegrant, a lubricant, a coloring agent, etc. are added to the salt of compound (I) or a crystal thereof as necessary. Thus, tablets, granules, powders and capsules can be produced. Tablets, granules, powders, capsules and the like may be coated as necessary.
As the excipient, for example, lactose, crystalline cellulose and the like, as the binder, for example, hydroxypropyl cellulose and the like, as the disintegrant, for example, croscarmellose sodium and the like, as the lubricant, for example, Examples of the colorant include magnesium stearate, titanium oxide, and the like, and examples of the coating agent include, but are not limited to, hydroxypropylmethylcellulose and the like.
These solid preparations such as tablets, capsules, granules, powders and the like can usually contain any amount of the salt of compound (I) or a crystal thereof as long as it shows a medicinal effect that can be used as a medicine.

In the case of producing an injection (for intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, etc.), if necessary, a pH adjusting agent is added to the salt of compound (I) or a crystal thereof. Buffering agents, suspending agents, solubilizing agents, antioxidants, preservatives (preservatives), isotonic agents and the like can be added to produce injections by conventional methods. Alternatively, it may be freeze-dried to obtain a freeze-dried preparation that is dissolved at the time of use.
Examples of pH adjusters and buffers include organic acids or inorganic acids and / or pharmaceutically acceptable salts thereof, and examples of suspending agents include hydroxypropyl cellulose and the like as solubilizers. Is, for example, polysorbate 80, etc., as an antioxidant, for example, α-tocopherol, etc., as a preservative, for example, methyl paraoxybenzoate, ethyl paraoxybenzoate, etc. , Glucose and the like can be mentioned, but are not limited thereto.
These injections can usually contain any amount of the salt of compound (I) or a crystal thereof as long as it shows a medicinal effect that can be used as a medicine.

In the case of producing an external preparation, a base material is added to the salt of compound (I) or a crystal thereof, and if necessary, for example, the above-mentioned preservative, pH adjuster, antioxidant, coloring agent, etc. In addition, for example, transdermal preparations (ointments, patches, etc.), eye drops, nasal drops, suppositories and the like can be produced by conventional methods.
As the base material to be used, for example, various raw materials usually used for pharmaceuticals, quasi drugs, cosmetics and the like can be used. Specifically, for example, animal and vegetable oils, mineral oils, ester oils, waxes, emulsifiers, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers And raw materials such as clay minerals and purified water.
These external preparations can usually contain any amount of a salt of compound (I) or a crystal thereof as long as it shows a medicinal effect that can be used as a pharmaceutical product.

  The dosage of the salt of Compound (I) or crystals thereof varies depending on the degree of symptoms, age, sex, body weight, dosage form / salt type, specific type of disease, etc., without causing unacceptable side effects. Although it is not limited as long as the maximum dose of the drug that can be administered is not exceeded, it is usually about 30 μg to 10 g, such as 100 μg to 5 g, for example 100 μg to 1 g, or about 30 μg 1 g, for example, 100 μg to 500 mg, further 100 μg to 300 mg, for example, is administered once or in several divided doses.

  The compounds according to the present invention can be produced, for example, by the methods described in the following production examples and examples. However, these are illustrative, and the compound according to the present invention is not limited to the following specific examples in any case.

  In the powder X-ray crystal diffraction of the crystals produced in the following production examples, examples and reference examples, the obtained crystals were placed on a sample stage of a powder X-ray diffractometer and analyzed under the following conditions. The results are shown in FIGS. 1-3 and 6-15.

Measurement conditions Sample holder: Aluminum Target: Copper Detector: Scintillation counter Tube voltage: 50kV
Tube current: 300mA
Slit: DS 0.5 mm (Height limiting slit 2 mm), SS Open, RS Open
Scanning speed: 10 ° / min Sampling interval: 0.02 °
Scanning range: 5-35 °

The ¹³ C solid state NMR spectrum of the crystal was measured under the following conditions. The result is shown in FIG.
Measuring condition use device: AVANCE400 (manufactured by BRUKER)
Measurement temperature: Room temperature (22 ° C)
Reference substance: Glycine (External standard: 176.03 ppm)
Measurement nucleus: 13C (100.6248425MHz)
Pulse repetition time: 3 seconds Pulse mode: TOSS measurement

  In the production examples, unless otherwise specified, silica gel 60 (Kanto Chemicals) or Presep Silica Gel (WAKO) was used as the silica gel for purification used in silica gel column chromatography. Moreover, the silica gel for refinement | purification used for NH silica gel column chromatography used NH silica gel (Fuji Silisia Chemical LTD.) Or Hi-Flash Column Amino (YAMAZENE CORPORATION).

  The proton nuclear magnetic resonance spectrum was measured using a Varian Mercury 400, Varian Mercury Plus 400, Varian INOVA 500 or Avance 600 MHz (Bruker) at 400 MHz unless otherwise specified. The chemical shift of the proton nuclear magnetic resonance spectrum is recorded in δ units (ppm) relative to tetramethylsilane, and the coupling constant is recorded in hertz (Hz). The abbreviations of the division pattern are as follows. s: singlet, d: doublet, t: triplet, m: multiplet, brs: broad singlet.

  In the production examples, examples and reference examples, commercially available compounds were appropriately used as the commercially available compounds.

[Production Example 1-1] N- (4-chloropyridin-2-yl) acetamide
Commercially available 2-amino-4-chloropyridine (50 g, 389 mmol) was dissolved in acetic anhydride (500 mL), triethylamine (271 mL, 1.94 mol) was added at 20 ° C., and the mixture was stirred at 60 ° C. for 12 hours. After cooling to room temperature, the solvent was distilled off. The residue was purified by silica gel column chromatography (n-heptane: ethyl acetate = 4: 1 to 1: 1), and the target fraction was concentrated under reduced pressure to obtain the title compound (66 g, 99%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 2.21 (3H, s), 7.05 (1H, dd, J = 5.4, 1.9 Hz), 8.15 (1H, d, J = 5.4 Hz), 8.30 (2H , brs).

[Production Example 1-2] Phenyl methyl carbamate
A mixture of commercially available methylamine hydrochloride (50 g, 0.74 mol), pyridine (124 mL, 1.53 mol) and N, N-dimethylformamide (500 mL) was stirred at 5 ° C., and commercially available phenyl chlorocarbonate (94 mL, 0.75 mol) was added dropwise over 2 hours. After dropping, the mixture was stirred at room temperature for 16 hours under a nitrogen atmosphere. The reaction mixture was added to ice water (2 L) and extracted twice with ethyl acetate (1.5 L). The organic layer was washed with water (1 L) and saturated brine (300 mL). The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off. N-Heptane and ethyl acetate were added to the concentrated residue, and the precipitate was collected by filtration using n-heptane and tert-butyl methyl ether to obtain the title compound (74.2 g, 66%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 2.90 (3H, d, J = 4.9 Hz), 4.95 (1H, brs), 7.08-7.16 (2H, m), 7.16-7.24 (1H, m) , 7.31-7.41 (2H, m).

[Production Example 1-3] 1- (4-phenylpiperidin-1-yl) ethanone
A mixture of commercially available 4-phenylpiperidine (10 g, 62 mmol), pyridine (5.7 mL, 70.5 mmol) and tetrahydrofuran (80 mL) was stirred at 0 ° C., and acetyl chloride (5 mL, 70.3 mmol) and tetrahydrofuran (20 mL) were stirred. ) Was added dropwise over 10 minutes. The mixture was stirred at 25 ° C. for 14 hours under a nitrogen atmosphere. Ethyl acetate (100 mL) and water (100 mL) were added to the reaction solution and the phases were separated. The aqueous layer was extracted with ethyl acetate (100 mL), and the organic layers were combined and washed with saturated aqueous sodium hydrogen carbonate solution (100 mL), water (100 mL), and then saturated brine (50 mL). The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off to obtain the title compound (12.3 g, 98%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 1.52-1.78 (2H, m), 1.81-1.99 (2H, m), 2.14 (3H, s), 2.63 (1H, td, J = 12.9, 2.7 Hz), 2.74 (1H, tt, J = 12.1, 3.7 Hz), 3.17 (1H, td, J = 13.2, 2.6 Hz), 3.84-4.02 (1H, m), 4.69-4.89 (1H, m), 7.08 -7.43 (5H, m).

[Production Example 1-4] 4- (1-acetylpiperidin-4-yl) benzoic acid
A mixture of aluminum (III) chloride (26 g, 195 mmol) and dichloromethane (200 mL) was stirred at 0 ° C., and oxalyl chloride (20 mL, 228 mmol) was added dropwise over 10 minutes. Subsequently, a mixture of 1- (4-phenylpiperidin-1-yl) ethanone (12.3 g, 60.5 mmol) and dichloromethane (50 mL) described in Production Example 1-3 was added dropwise over 30 minutes. The mixture was stirred at 25 ° C. for 14 hours under a nitrogen atmosphere. The reaction mixture was poured into ice, and ethyl acetate (1 L) and water (1 L) were added to separate the layers. The aqueous layer was extracted twice with ethyl acetate (1 L), and then the organic layer was washed twice with water (1 L) followed by saturated brine (500 mL). The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off. Ethyl acetate was added to the concentrated residue, and the product was filtered and washed with ethyl acetate to obtain the title compound (9.09 g, 61%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 1.49-1.82 (2H, m), 1.92 (2H, t, J = 13.2 Hz), 2. 15 (3H, s), 2.65 (1H, t, J = 11.7 Hz), 2.75-2.94 (1H, m), 3.08-3.30 (1H, m), 3.97 (1H, d, J = 13.2 Hz), 4.82 (1H, d, J = 12.8 Hz), 7.30 ( 2H, d, J = 8.4 Hz), 8.05 (2H, d, J = 8.1 Hz).

[Production Example 1-5] 4- (Piperidin-4-yl) benzoic acid hydrochloride
A mixture of 4- (1-acetylpiperidin-4-yl) benzoic acid (4.50 g, 18.2 mmol) and 5M hydrochloric acid (50 mL, 250 mmol) described in Production Example 1-4 at 140 ° C. under a nitrogen atmosphere. Stir for 18 hours. After cooling to room temperature, the product was collected by filtration and washed with water to give the title compound (3.77 g, 86%).
¹ H-NMR Spectrum (DMSO-d ₆ ) δ (ppm): 1.60-2.15 (4H, m), 2.76-3.16 (3H, m), 3.27-3.45 (2H, m), 7.36 (2H, d, J = 8.1 Hz), 7.92 (2H, d, J = 8.1 Hz), 8.65-9.04 (2H, m), 12.89 (1H, brs).

[Production Example 1-6] 4- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid
A mixture of 4- (piperidin-4-yl) benzoic acid hydrochloride (2.00 g, 8.27 mmol), 1M sodium hydroxide solution (25 mL, 25 mmol) and acetone (50 mL) described in Preparation Example 1-5 was added. The mixture was stirred at 0 ° C., and a solution of di-tert-butyl dicarbonate (1.9 g, 8.71 mmol) in acetone (25 mL) was added dropwise over 10 minutes. The mixture was stirred at 25 ° C. for 18 hours under a nitrogen atmosphere. Under cooling at 0 ° C., 1M hydrochloric acid (17 mL) was added. Extraction was performed twice with ethyl acetate (100 mL). The organic layer was washed with saturated brine (50 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. N-Heptane and tert-butyl methyl ether were added to the concentrated residue, and the product was filtered and washed with n-heptane to obtain the title compound (2.30 g, 91%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 1.49 (9H, s), 1.57-1.76 (2H, m), 1.84 (2H, d, J = 13.5 Hz), 2.62-2.97 (3H, m) , 4.27 (2H, brs), 7.28-7.36 (2H, m), 7.98-8.10 (2H, m).

[Production Example 1-7] 3-Hydroxy-4- (2-methoxyethoxy) benzaldehyde
Commercially available 3,4-dihydroxybenzaldehyde (39.3 g, 285 mmol) and sodium carbonate (45.2 g, 427 mmol) were dissolved in N, N-dimethylformamide (400 mL), and then commercially available at room temperature under a nitrogen atmosphere. -Bromoethyl methyl ether (26.7 mL, 285 mmol) was added and stirred for 5 days. After cooling to 0 ° C., 2M hydrochloric acid, ethyl acetate and water were added and partitioned. The aqueous layer was extracted with ethyl acetate, and the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. After the solvent was distilled off and dichloromethane was added, the precipitate was separated by filtration, and the obtained filtrate was purified by silica gel column chromatography (n-heptane: ethyl acetate = 17: 3 to 1: 1). The target fraction was concentrated under reduced pressure to obtain the title compound (12.9 g, 23%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 3.47 (3H, s), 3.76-3.80 (2H, m), 4.25-4.29 (2H, m), 6.40 (1H, brs), 7.01 (1H, d, J = 8.4 Hz), 7.41 (1H, dd, J = 8.2, 2.0 Hz), 7.45 (1H, d, J = 1.8 Hz), 9.85 (1H, s).

[Production Example 1-8] 3- (Benzyloxy) -4- (2-methoxyethoxy) benzaldehyde
To a mixture of 3-hydroxy-4- (2-methoxyethoxy) benzaldehyde (12.9 g, 65.9 mmol) and ethanol (130 mL) described in Production Example 1-7, potassium carbonate (11. 8 g, 85.7 mmol) and benzyl chloride (10 mL, 86.9 mmol) were added, and the mixture was heated and stirred at 90 ° C. for 2 hours. After cooling to 0 ° C., 2M hydrochloric acid, ethyl acetate and water were added and partitioned. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and filtered. The solvent was distilled off, and the resulting residue was purified by silica gel column chromatography (n-heptane: ethyl acetate = 9: 1 to 1: 1). The target fraction was concentrated under reduced pressure to obtain the title compound (17.6 g, 93%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 3.46 (3H, s), 3.79-3.85 (2H, m), 4.24-4.30 (2H, m), 5.18 (2H, s), 7.03 (1H, d, J = 8.1 Hz), 7.29-7.35 (1H, m), 7.35-7.41 (2H, m), 7.43-7.50 (4H, m), 9.82 (1H, s).

[Production Example 1-9] (E) -2- (benzyloxy) -1- (2-methoxyethoxy) -4- (2-nitrovinyl) benzene
3- (Benzyloxy) -4- (2-methoxyethoxy) benzaldehyde (17.6 g, 61.5 mmol) described in Production Example 1-8 was dissolved in acetic acid (49.3 mL). Ammonium acetate (5.69 g, 73.8 mmol) and nitromethane (8.32 mL, 154 mmol) were added at room temperature, and the mixture was heated with stirring at 130 ° C. for 2 hours. After cooling to room temperature, the precipitate was collected by filtration and washed with ethanol to give the title compound quantitatively.
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 3.46 (3H, s), 3.78-3.84 (2H, m), 4.21-4.27 (2H, m), 5.16 (2H, s), 6.97 (1H, d, J = 8.4 Hz), 7.06 (1H, d, J = 1.8 Hz), 7.16 (1H, dd, J = 8.4, 2.2 Hz), 7.30-7.48 (6H, m), 7.91 (1H, d, J = 13.5 Hz).

[Production Example 1-10] 6- (2-methoxyethoxy) -1H-indole-5-ol
(E) -2- (benzyloxy) -1- (2-methoxyethoxy) -4- (2-nitrovinyl) benzene (20.2 g, 61.5 mmol) and acetic acid (120 mL) described in Preparation Example 1-9 69% nitric acid (15 mL, 233 mmol) was added to the mixture at 25 ° C., and the mixture was stirred at room temperature for 6 hours. The reaction mixture was poured into ice, and the precipitate was collected by filtration and washed with water to obtain a crude product (23.0 g).
The crude product (23.0 g) was suspended in methanol (500 mL), 10% palladium-carbon (50% water-containing product) (8 g) was added at room temperature, and the mixture was stirred under a hydrogen atmosphere for 6 hr. The catalyst was filtered through celite, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (n-heptane: ethyl acetate = 2: 1 to 1: 1). The target fraction was concentrated under reduced pressure to obtain the title compound (3.94 g, 31%).
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 3.48 (3H, s), 3.69-3.78 (2H, m), 4.16-4.23 (2H, m), 6.24 (1H, s), 6.41 (1H, ddd, J = 3.1, 2.1, 0.8 Hz), 6.97 (1H, s), 7.10 (1H, dd, J = 3.2, 2.5 Hz), 7.15 (1H, s), 7.94 (1H, brs).

[Production Example 1-11] N- (4-((6- (2-methoxyethoxy) -1H-indol-5-yl) oxy) pyridin-2-yl) acetamide
6- (2-methoxyethoxy) -1H-indole-5-ol (3.94 g, 19.0 mmol) described in Preparation Example 1-10, N- (4-chloropyridine- described in Preparation Example 1-1 2-yl) acetamide (3.25 g, 19.0 mmol) was dissolved in dimethyl sulfoxide (25 mL), 97% potassium tert-butoxide (2.20 g, 19.0 mmol) was added at room temperature, and 13 at 150 ° C. Stir with heating for hours. The reaction solution was partitioned by adding water and ethyl acetate at room temperature. The aqueous layer was extracted 3 times with ethyl acetate, and the combined organic layers were washed with water. The organic layer was dried over anhydrous sodium sulfate. The desiccant was filtered, and the filtrate was concentrated under reduced pressure, and then purified by NH silica gel column chromatography (n-heptane: ethyl acetate = 2: 3 to 0: 1 to ethyl acetate: methanol = 49: 1 to 9: 1). The target fraction was concentrated under reduced pressure to obtain the title compound (3.45 g, 53%).
¹ H-NMR Spectrum (500MHz, CDCl ₃ ) δ (ppm): 2.13 (3H, s), 3.27 (3H, s), 3.54-3.58 (2H, m), 4.07-4.11 (2H, m), 6.46- 6.50 (1H, m), 6.54 (1H, dd, J = 5.8, 1.9 Hz), 7.05 (1H, s), 7.14-7.17 (1H, m), 7.36 (1H, s), 7.75 (1H, brs) , 8.02 (1H, d, J = 5.8 Hz), 8.10 (1H, brs), 8.19 (1H, brs).

[Production Example 1-12] 4-((6- (2-methoxyethoxy) -1H-indol-5-yl) oxy) pyridin-2-amine
N- (4-((6- (2-methoxyethoxy) -1H-indol-5-yl) oxy) pyridin-2-yl) acetamide (3.45 g, 10.1 mmol) described in Preparation Example 1-11 Was dissolved in methanol (50 mL), 2M sodium hydroxide solution (50 mL) was added at room temperature, and the mixture was stirred with heating at 70 ° C. for 3 hr. The reaction mixture was partitioned by adding water and ethyl acetate. The aqueous layer was extracted 3 times with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. The desiccant was filtered, the filtrate was concentrated under reduced pressure, and purified by NH silica gel column chromatography (n-heptane: ethyl acetate = 3: 7 to 0: 1 to ethyl acetate: methanol = 49: 1 to 24: 1). The target fraction and the mixture fraction were separately concentrated under reduced pressure, and the mixture fraction was purified again by silica gel column chromatography (ethyl acetate: methanol = 1: 0 to 9: 1) and combined with the previous target fraction. This gave the title compound (2.60 g, 86%).
¹ H-NMR Spectrum (500MHz, CDCl ₃ ) δ (ppm): 3.31 (3H, s), 3.58-3.63 (2H, m), 4.08-4.11 (2H, m), 4.28 (2H, brs), 5.90 ( 1H, d, J = 2.4 Hz), 6.29 (1H, dd, J = 6.1, 2.2 Hz), 6.44-6.52 (1H, m), 7.06 (1H, s), 7.15-7.20 (1H, m), 7.34 (1H, s), 7.88 (1H, d, J = 5.8 Hz), 8.22 (1H, brs).

[Production Example 1-13] 5-[(2-Aminopyridin-4-yl) oxy] -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide
4-((6- (2-methoxyethoxy) -1H-indol-5-yl) oxy) pyridin-2-amine (2.60 g, 8.67 mmol) described in Preparation Example 1-12 was converted to N, N- Dissolved in dimethylformamide (50 mL), 50-72% sodium hydride oil (499 mg) was added at room temperature under nitrogen atmosphere. Phenyl methyl carbamate (1.97 g, 13.0 mmol) described in Production Example 1-2 was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was cooled to 0 ° C., and partitioned by adding ethyl acetate and water. The aqueous layer was extracted twice with ethyl acetate, sodium chloride was added to the aqueous layer and extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. The desiccant was filtered, the filtrate was concentrated under reduced pressure, and purified by NH silica gel column chromatography (n-heptane: ethyl acetate = 1: 4 to 0: 1 to ethyl acetate: methanol = 49: 1 to 24: 1). The target fraction was concentrated under reduced pressure, ethyl acetate was added, and the precipitate was collected by filtration and washed to obtain the title compound (2.23 g, 72%).
¹ H-NMR Spectrum (500MHz, CDCl ₃ ) δ (ppm): 3.06 (3H, d, J = 4.9 Hz), 3.29 (3H, s), 3.59-3.63 (2H, m), 4.14-4.17 (2H, m), 4.30 (2H, brs), 5.52-5.59 (1H, m), 5.89 (1H, d, J = 2.4 Hz), 6.27 (1H, dd, J = 5.8, 1.9 Hz), 6.55 (1H, d , J = 3.9 Hz), 7.27-7.29 (2H, m), 7.89 (1H, d, J = 5.9 Hz), 7.99 (1H, s).

[Production Example 1-14] 6- (2-methoxyethoxy) -N-methyl-5-{[2-({[4- (piperidin-4-yl) phenyl] carbonyl} amino) pyridin-4-yl] Oxy} -1H-indole-1-carboxamide
Benzotriazole (609 mg, 5.11 mmol) was dissolved in dichloromethane (25 mL), thionyl chloride (373 μL, 5.11 mmol) was added at room temperature under a nitrogen atmosphere, and the mixture was stirred for 5 min. 4- (1- (tert-Butoxycarbonyl) piperidin-4-yl) benzoic acid (1.3 g, 4.26 mmol) described in Production Example 1-6 was added to the reaction mixture at room temperature, and the mixture was stirred for 30 minutes. The reaction mixture was filtered through a glass filter lined with anhydrous sodium sulfate, washed with dichloromethane, and the filtrate was prepared according to 5-[(2-aminopyridin-4-yl) oxy] -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide (0.95 g, 2.67 mmol), triethylamine (1.86 mL, 13.3 mmol), 4-dimethylaminopyridine (16 mg, 0.133 mmol), The mixture was added to a mixture of N, N-dimethylformamide (3 mL) and dichloromethane (20 mL) at 0 ° C. over 5 minutes, washed with dichloromethane (10 mL), and stirred at the same temperature for 5 minutes. After stirring at room temperature for 2 hours, 40% aqueous methylamine solution (2.3 mL, 26.7 mmol) was added, and the mixture was stirred at room temperature for 1.5 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture for partitioning, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. After filtering the desiccant, the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (n-heptane: ethyl acetate = 1: 1 to 0: 1 to ethyl acetate: methanol = 49: 1 to 23: 2) and crude. The product (1.11 g) was obtained.
The crude product (1.11 g) was dissolved in dichloromethane (50 mL) and trifluoroacetic acid (5.0 mL) was added at room temperature. The mixture was stirred at room temperature for 30 minutes and concentrated under reduced pressure. The residue was dissolved in dichloromethane and triethylamine and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate: methanol = 1: 0 to 22: 3) to obtain the title compound (829 mg, 57%).
¹ H-NMR Spectrum (500MHz, CDCl ₃ ) δ (ppm): 1.59-1.69 (2H, m), 1.83 (2H, d, J = 14.1 Hz), 2.68 (1H, tt, J = 12.0, 3.6 Hz) , 2.75 (2H, td, J = 12.2, 2.4 Hz), 3.04 (3H, d, J = 4.9 Hz), 3.17-3.23 (2H, m), 3.26 (3H, s), 3.55-3.61 (2H, m ), 4.15-4.21 (2H, m), 5.57-5.65 (1H, m), 6.53 (1H, d, J = 3.4 Hz), 6.62 (1H, dd, J = 5.8, 2.4 Hz), 7.25 (1H, d, J = 3.9 Hz), 7.30-7.34 (3H, m), 7.77-7.82 (2H, m), 7.91 (1H, d, J = 2.4 Hz), 8.02 (1H, s), 8.10 (1H, d , J = 5.9 Hz), 8.50 (1H, brs).

[Production Example 1-15] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 (2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide
6- (2-methoxyethoxy) -N-methyl-5-{[2-({[4- (piperidin-4-yl) phenyl] carbonyl} amino) pyridin-4-yl described in Preparation Example 1-14 ] Oxy} -1H-indole-1-carboxamide (100 mg, 0.18 mmol) and tetrahydrofuran (4 mL) were mixed with sodium triacetoxyborohydride (114 mg, 0.54 mmol) and commercially available 2-hydroxy at room temperature. Acetaldehyde (34.4 mg, 0.57 mmol) was added and stirred at room temperature for 2 hours. The reaction mixture was partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The aqueous layer was extracted with ethyl acetate, and the combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The solvent was distilled off, and the resulting residue was purified by NH silica gel column chromatography (ethyl acetate: methanol = 1: 0 to 97: 3 to 9: 1). The target fraction was concentrated under reduced pressure, and the precipitate was collected by filtration with a mixed solution of diethyl ether and n-hexane and washed to obtain the title compound (90 mg, 83%). A representative powder X-ray diffraction angle of the obtained compound is shown (Compound (I) -Free Form A). (2θ ± 0.2 °): 10.4 °, 10.9 °, 11.4 °, 13.5 °, 16.1 °, 19.7 °, 20.4 °, 21.5 °, 23 .3 ° and 24.3 °.
¹ H-NMR Spectrum (CDCl ₃ ) δ (ppm): 1.70-1.92 (4H, m), 2.15-2.24 (2H, m), 2.53-2.65 (3H, m), 3.01-3.09 (5H, m), 3.26 (3H, s), 3.56-3.60 (2H, m), 3.64 (2H, t, J = 5.2 Hz), 4.15-4.20 (2H, m), 5.49-5.54 (1H, m), 6.55 (1H, d, J = 3.7 Hz), 6.61 (1H, dd, J = 5.8, 2.3 Hz), 7.24-7.28 (1H, m), 7.30-7.35 (3H, m), 7.81 (2H, d, J = 8.2 Hz ), 7.91 (1H, d, J = 2.4 Hz), 8.01 (1H, s), 8.10 (1H, d, J = 5.9 Hz), 8.50 (1H, brs).

[Example 1] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 succinate (other name: 5-({2-[({4- [1- (2-hydroxyethyl) piperidine-4- Yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide butanedioate (2: 3)) Preparation

5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 -(2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 2.93 g was weighed into an eggplant flask, 60 mL of ethanol was added, and the mixture was heated to 70 ° C. in an oil bath with stirring and dissolved. . Succinic acid (1.23 g) was added, and the oil bath was cut and cooled slowly. After stirring at room temperature for about 2 hours, the mixture was further stirred at 5 ° C. for 1 hour. The solid was collected by filtration to give the title compound (3.70 g).
¹ H-NMR Spectrum (600MHz, CD ₃ OD) δ (ppm): 1.96-2.10 (4H, m), 2.52 (6H, s), 2.93 (1H, m), 2.96 (3H, s), 3.01 (2H , m), 3.16 (2H, t, J = 5.4 Hz), 3.22 (3H, s), 3.56 (2H, t, J = 4.7 Hz), 3.61 (2H, m), 3.87 (2H, t, J = 5.4 Hz), 4.14 (2H, t, J = 4.6 Hz), 6.61 (1H, d, J = 3.6 Hz), 6.68 (1H, dd, J = 5.8, 2.3 Hz), 7.37 (1H, s), 7.42 (2H, d, J = 8.3 Hz), 7.58 (1H, d, J = 3.6 Hz), 7.73 (1H, d, J = 2.2 Hz), 7.88 (2H, d, J = 8.3 Hz), 8.08 (1H , s), 8.15 (1H, d, J = 5.8 Hz).
¹³ C-NMR (100 MHz, solid state) δ (ppm): 27.1, 28.3, 29.7, 34.8, 38.0, 41.3, 54.0, 57.3, 59.7, 60.9, 72.1, 72.5, 103.3, 104.2, 108.5, 116.9, 126.9, 128.6 , 134.5, 136.7, 140.7, 149.4, 151.3, 155.1, 169.5, 170.1, 175.6, 179.9, 183.7.

[Example 2] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide Preparation of 0.5 Succinate Crystals (α)

5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 117 mg of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid (11.8 mg) were added to a 30 mL eggplant flask and isopropanol / water (8/2, v / v) 2 mL of the solution was added, and after ultrasonic irradiation, the mixture was stirred at room temperature for 2 to 3 hours. This was collected by filtration to give the title compound (77.5 mg).
¹ H-NMR Spectrum (600MHz, CD ₃ OD) δ (ppm): 1.86-2.00 (4H, m), 2.51 (2H, s), 2.62 (2H, m), 2.79 (1H, m), 2.87 (2H , t, J = 5.5 Hz), 2.96 (3H, s), 3.22 (3H, s), 3.36 (2H, d, J = 11.8 Hz), 3.56 (2H, t, J = 4.6 Hz), 3.79 (2H , t, J = 5.7 Hz), 4.15 (2H, t, J = 4.6 Hz), 6.61 (1H, d, J = 3.6 Hz), 6.68 (1H, dd, J = 5.7, 2.1 Hz), 7.37 (1H , s), 7.40 (2H, d, J = 8.2 Hz), 7.58 (1H, d, J = 3.6 Hz), 7.73 (1H, d, J = 2.0 Hz), 7.86 (2H, d, J = 8.3 Hz) ), 8.08 (1H, s), 8.14 (1H, d, J = 5.8 Hz).

[Example 3] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 Preparation of crystals of -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide maleate

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 -(2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide Maleic acid (24.1 mg) and 2 mL of acetone were added to 101 mg, and the mixture was stirred at room temperature overnight. The solid was collected by filtration to give the title compound (113 mg).

[Example 4] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide Preparation of 0.5 Succinate Crystals (α)

5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy)- N-methyl-1H-indole-1-carboxamide 550 mg, succinic acid 55.3 mg, and water 5.5 mL were added to a test tube, and the mixture was stirred overnight at room temperature after ultrasonic irradiation. Filtered overnight using a filter. After grinding in an agate mortar, it was stored at 40 ° C./75% RH for about 1.5 hours to obtain the title compound (620 mg).
¹ H-NMR Spectrum (CD ₃ OD) δ (ppm): 1.86-2.00 (4H, m), 2.51 (2H, s), 2.62 (2H, m), 2.79 (1H, m), 2.87 (2H, brt , J = 5.5 Hz), 2.96 (3H, s), 3.22 (3H, s), 3.36 (2H, brd, J = 11.8 Hz), 3.56 (2H, brt, J = 4.6 Hz), 3.79 (2H, t , J = 5.7 Hz), 4.15 (2H, brt, J = 4.6 Hz), 6.61 (1H, d, J = 3.6 Hz), 6.68 (1H, dd, J = 5.7, 2.1 Hz), 7.37 (1H, s ), 7.40 (2H, d, J = 8.2 Hz), 7.58 (1H, d, J = 3.6 Hz), 7.73 (1H, d, J = 2.0 Hz), 7.86 (2H, d, J = 8.3 Hz), 8.08 (1H, s), 8.14 (1H, d, J = 5.8 Hz)

Example 5 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide Preparation of 0.5 succinate crystals (β)

The sample obtained in Example 4 was dried under reduced pressure for 3 days to give the title compound.
¹ H-NMR Spectrum (CD ₃ OD) δ (ppm): 1.87-2.00 (4H, m), 2.51 (2H, s), 2.65 (2H, m), 2.79 (1H, m), 2.89 (2H, brt , J = 5.6 Hz), 2.95 (3H, s), 3.22 (3H, s), 3.38 (2H, brd, J = 12.1 Hz), 3.56 (2H, m), 3.80 (2H, t, J = 5.6 Hz ), 4.14 (2H, m), 6.60 (1H, d, J = 3.7 Hz), 6.67 (1H, dd, J = 5.8, 2.3 Hz), 7.37 (1H, s), 7.40 (2H, d, J = 8.4 Hz), 7.57 (1H, d, J = 3.7 Hz), 7.73 (1H, d, J = 2.3 Hz), 7.86 (2H, d, J = 8.4 Hz), 8.08 (1H, s), 8.14 (1H , d, J = 5.8 Hz)

[Example 6] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 Preparation of amorphous succinate

5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy)- 251 mg of N-methyl-1H-indole-1-carboxamide 1.5 succinate was dissolved in 25 mL of 50% aqueous tert-butyl alcohol. 3 mL of the solution was added to the test tube and frozen with ethanol cooled with dry ice. The solvent was removed by lyophilization to give the title compound (30.8 mg).
¹ H-NMR Spectrum (CD ₃ OD) δ (ppm): 1.96-2.11 (4H, m), 2.53 (6H, s), 2.93 (1H, m), 2.96 (3H, s), 3.00 (2H, m ), 3.15 (2H, t, J = 5.4 Hz), 3.22 (3H, s), 3.56 (2H, m), 3.60 (2H, brd, J = 12.4 Hz), 3.87 (2H, t, J = 5.5 Hz) ), 4.15 (2H, brt, J = 4.6 Hz), 6.61 (1H, d, J = 3.7 Hz), 6.68 (1H, brd, J = 3.8 Hz), 7.37 (1H, s), 7.42 (2H, d , J = 8.3 Hz), 7.58 (1H, d, J = 3.8 Hz), 7.73 (1H, brs), 7.88 (2H, d, J = 8.3 Hz), 8.08 (1H, s), 8.15 (1H, brd , J = 5.0 Hz)

[Reference Example 1] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide crystals (Free Form B)

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 93.2 mg of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide was weighed into a test tube, and 2.99 mL of isopropanol and 264 μL of water were added. The sample was dissolved by heating in an oil bath at 70 to 100 ° C. This solution was stirred for about 16 hours in a thermostatic bath at -5 ° C. The precipitated solid was collected by filtration and dried under reduced pressure overnight to obtain the title compound. The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 7.8 °, 10.8 °, 13.1 °, 14.2 °, 17.8 °, 21.5 °, 21.7 °, 23.4 °, 24 .5 ° and 29.0 °.

[Reference Example 2] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide hydrate crystals (Free Form Hydrate)

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 To 208 mg of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide was added 2 mL of isopropanol and 2 mL of water. After ultrasonic irradiation in ice water, the mixture was stirred at about 5 ° C. for 3 days. The suspended solid was collected by filtration to give the title compound (106 mg). The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 8.8 °, 9.6 °, 15.2 °, 16.3 °, 20.0 °, 20.8 °, 21.4 °, 22.0 °, 23 .8 ° and 27.1 °.

[Reference Example 3] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 Preparation of crystals of -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide mesylate

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 -(2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide After adding 2 mL of acetone to 30.1 mg, mesylic acid (4.0 μL) was added, and the mixture was stirred at room temperature for 4 days. The solid was collected by filtration to give the title compound (20.4 mg). The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 11.7 °, 13.7 °, 15.2 °, 16.9 °, 18.0 °, 18.7 °, 19.9 °, 21.1 °, 22 0.0 ° and 24.1 °.

[Reference Example 4] 5-((2- (4- (1- (2-hydroxyethyl) piperidin-4-yl) benzamido) pyridin-4-yl) oxy) -6- (2-methoxyethoxy) -N -Methyl-1H-indole-1-carboxamide tosylate crystal preparation

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 -(2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide After adding 2 mL of acetone to 30.7 mg, p-toluenesulfonic acid monohydrate (12.3 mg) was added and Stir for days. The solid was collected by filtration to give the title compound (15.1 mg). The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 11.9 °, 12.6 °, 13.5 °, 13.8 °, 17.6 °, 18.0 °, 18.6 °, 20.4 °, 21 .4 ° and 23.3 °.

[Reference Example 5] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide Preparation of benzoate crystals

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 0.2 mL of ethyl acetate was added to a mixture of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 20.3 mg and benzoic acid (8.91 mg), and the mixture was stirred at room temperature. After 2 hours, 0.1 mL of ethyl acetate was added, and the mixture was further stirred overnight. The solid was collected by filtration to give the title compound. The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 9.3 °, 13.9 °, 14.5 °, 15.8 °, 18.1 °, 19.4 °, 20.5 °, 21.3 °, 22 .6 ° and 26.2 °.

[Reference Example 6] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 Preparation of crystals of -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide fumarate

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 2 mL of acetone was added to a mixture of 30.6 mg of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and fumaric acid (7.24 mg) and stirred overnight at room temperature. The solid was collected by filtration to give the title compound. The representative powder X-ray diffraction angle of the obtained compound is shown. (2θ ± 0.2 °): 9.6 °, 13.8 °, 15.7 °, 16.7 °, 19.8 °, 21.0 °, 22.0 °, 22.4 °, 24 .7 ° and 25.7 °.

[Reference Example 7] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 Preparation of -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide hydrochloride

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 -(2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 29.5 mg of acetone and 6N hydrochloric acid (10.0 μL) were added to 29.5 mg and the mixture was stirred at room temperature. As an oil.

[Reference Example 8] 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2 Preparation of -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide hydrobromide

  5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6 described in Preparation Example 1-15 2 mL of acetone and hydrobromic acid (7.8 μL) were added to 32.7 mg of-(2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide, and the mixture was stirred at room temperature. Separated from the solvent as an oil.

[Test example]
The following test examples were conducted to examine the physical properties or pharmacological effects of the compound (I) or the salt of compound (I) described in Production Example 1-15 or crystals thereof.

[Test Example 1] Hygroscopicity The hygroscopicity of the compound (I) · 1.5 succinate of Example 1 was evaluated using a dynamic moisture adsorption measuring apparatus. The sample mounting part of the apparatus was kept at 25 ° C., and the relative humidity (RH) was set stepwise in the range of 5% to 95%. Humidity was adjusted by changing the relative flow rates of 0% RH dry nitrogen and 100% RH humidified nitrogen. The sample weight was confirmed with a microbalance every 2 minutes, and the humidity was sequentially changed when the weight fluctuation range for 5 minutes was less than 0.01%. The result is shown in FIG.

[Test Example 2] Cell-free kinase inhibitory action 1 μg of assay solution (20 mM HEPES-NaOH, 0.01% Triton X-100, ₂ mM DTT, 5 mM MgCl ₂ ) on a flat bottom 96 well white plate (Sumitomo Bakelite MS-8396W) 10 μL of an assay buffer solution containing 10 μl of FGFR1 protein (Carna Biosciences 08-133) diluted to / mL, final concentration of 1000 nM CSK-tide substrate (AnaSpec Inc 633843) and final concentration of 58.3 μM ATP (promega V9102) Then, 5 μl of a test substance diluted with an assay buffer was added and reacted at room temperature for 1 hour. ADP-Glo ^™ Kinase Assay (promega V9102) was used for the kinase activity measurement. To the plate after the reaction, 25 μL of ADP-Glo reagent was added to each well and reacted at room temperature for 40 minutes to stop the kinase reaction and deplete the remaining ATP. Further, Kinase detection reagent was added and reacted at room temperature for 40 minutes to perform conversion from ADP to ATP, luciferase / luciferin coupling reaction, and luminescence reaction by ATP. The enzyme activity was evaluated by measuring the amount of luminescence in each well using Envision ^™ (Perkin Elmer Co., Ltd.). Calculate the luminescence rate in the presence of the test substance, assuming that the luminescence when the kinase protein is added without adding the test substance is 100%, and the luminescence when the test substance and kinase protein are not added is 0%. It was. The concentration (IC ₅₀ value) of the test substance necessary to inhibit the kinase activity by 50% was calculated from this luminescence amount rate.

  Similar to the FGFR1 cell-free kinase inhibitory action, FGFR2 protein (Karna Biosciences 08-134), FGFR3 protein (Karna Biosciences 08-135), or FGFR4 protein (Karna Biosciences 08-136) was used. The FGFR2 cell-free kinase inhibitory action, the FGFR3 cell-free kinase inhibitory action, and the FGFR4 cell-free kinase inhibitory action were each measured. However, the ATP concentration was evaluated at a final concentration of 35 μM for FGFR2, 16.7 μM for FGFR3, and 75 μM for FGFR4. Regarding FGFR3 and FGFR4, the reaction time with the test substance was 2 hours at room temperature. These results are shown in Table 1.

<Cell-free kinase inhibitory action data>

[Test Example 3] SNU-16 Growth Inhibition Assay It has been reported that human gastric cancer cell line SNU-16 (ATCC Number CRL-5974) has FGFR2 gene amplification (Cancer Res. 2008.68: 2340-2348). SNU-16 cells were cultured and maintained in a 5% CO ₂ incubator (37 ° C.) using RPMI-1640 (WAKO 187-02021) medium containing 10% FBS and penicillin / streptomycin (WAKO 168-23191). To each well of a 96-well plate (Becton Dickinson 35-3075), 150 μL each of SNU-16 cell suspension prepared to 1 × 10 ⁴ cells / mL using RPMI-1640 medium containing 10% FBS was added. The cells were cultured overnight in a 5% CO ₂ incubator (37 ° C.). On the next day, 50 μL each of the test substance diluted in RPMI-1640 medium containing 10% FBS was added and cultured in a 5% CO ₂ incubator (37 ° C.) for 3 days. 10 μL of Cell Counting Kit-8 (Dojindo Laboratories CK04) was added to each well, and the cells were cultured in a 5% CO ₂ incubator (37 ° C.) for 1-2 hours for color development. Absorbance at 450 nm was measured by ENVISION ^™ (Perkin Elmer). Absorbance rate in the presence of the test substance was determined with the absorbance in the absence of the test substance being 100% and the absorbance of the well in which no cells were present being 0%. The concentration (IC ₅₀ value) of the test substance necessary to inhibit cell growth by 50% was determined and shown in Table 2.

<SNU-16 growth inhibitory action evaluation data>

Test Example 4 Antitumor Effect in Mouse SNU-16 Subcutaneous Transplant Model Human gastric cancer cell line SNU-16 cultured in RPMI-1640 culture solution containing 10% FBS and penicillin / streptomycin was treated with Hanks' Balanced Salt Solution (GIBCO # 24020 ) To a concentration of 1 × 10 ⁸ cells / mL and mixed 1: 1 with MATRIGEL (BD Bioscience Cat # 354234) to prepare a cell suspension of 5 × 10 ⁷ cells / ml. A nude mouse (BALB / cAJcl-nu / nu, female, Nippon Claire Co., Ltd.) of 6-7 weeks old was transplanted into the right flank subcutaneous part in a volume of 100 μL. Seven days after transplantation, the short axis and long axis of the tumor were measured using an electronic digital caliper (Digimatic TM caliper, Mitutoyo Corporation), and the tumor volume was calculated by the following formula.
Tumor volume (mm ³ ) = major axis (mm) × minor axis (mm) × minor axis (mm) / 2
Based on the tumor volume on the first day of administration, the groups were divided so that the average values of the tumor volumes were almost equal. The test substance was dissolved in DMSO, Tween 80 was added, a 10-fold concentrated solution was prepared, and stored frozen. Immediately before administration, a 5% glucose solution was added to obtain a final administration solution (DMSO: Tween 80: 5% glucose solution = 3.5%: 6.5%: 90%). The test sample was orally administered once a day for 11 days at a dose volume of 20 mL / kg, and the control solvent was orally administered under the same conditions. The experiment was conducted with 5 animals per group.
For each of the control group and the test substance-administered group, the weight ratio (RBW) of the last day to the weight of the first day is calculated. The test substance administration group in which the RBW of the test substance administration group / RBW of the control group was 0.9 or more was determined to be a safe administration group. For the test substance administration group corresponding to this, the ratio (T / C) (%) of the tumor volume after test substance administration to the control tumor volume on the last day was calculated and shown in Table 3.

<Anti-tumor effect evaluation data in SNU-16 subcutaneous transplantation model>

Claims (15)

5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy)-represented by the following formula (I) A salt comprising 6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid or maleic acid.
  The salt of claim 1 which is a succinate.   5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy)- The salt of claim 2 which is N-methyl-1H-indole-1-carboxamide 1.5 succinate.   5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy)- The salt of claim 2 which is N-methyl-1H-indole-1-carboxamide 0.5 succinate.   5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy)- The salt according to claim 1, which is N-methyl-1H-indole-1-carboxamide maleate. 5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy)-represented by the following formula (I) Crystal of salt consisting of 6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and succinic acid.
5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy)-represented by the following formula (I) Crystal of salt consisting of 6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide and maleic acid.
  In powder X-ray diffraction, 5-({2-[({4- [1- (2-hydroxyethyl) piperidine-4-] has a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 22.4 °. Yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 succinate crystals.   The crystal according to claim 8, having diffraction peaks at diffraction angles (2θ ± 0.2 °) of 22.4 °, 25.3 °, and 23.3 ° in powder X-ray diffraction.   In powder X-ray diffraction, 5-({2-[({4- [1- (2-hydroxyethyl) piperidine-4-] has a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 19.8 °. Yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 0.5 succinate crystals (α).   In powder X-ray diffraction, 5-({2-[({4- [1- (2-hydroxyethyl) piperidine-4-] has a diffraction peak at a diffraction angle (2θ ± 0.2 °) of 20.1 °. Yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide maleate crystals. ^{In the 13} C solid state NMR spectrum, 5-({2-[({4- [1- (2-hydroxyethyl) has peaks at chemical shifts (± 0.5 ppm) 108.5 ppm, 155.1 ppm and 179.9 ppm. ) Piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy) -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 Succinate crystals . The crystal according to claim 12, having peaks at chemical shifts (± 0.5 ppm) of 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm in a ¹³ C solid state NMR spectrum.   5-({2-[({4- [1- (2-hydroxyethyl) piperidin-4-yl] phenyl} carbonyl) amino] pyridin-4-yl} oxy having the powder X-ray diffraction pattern of FIG. ) -6- (2-Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide 1.5 Succinate crystals.   The pharmaceutical composition which contains the salt or crystal | crystallization as described in any one of Claims 1-14 as an active ingredient.